Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032756 | 0.94 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL4036042 | 0.88 | PKM (0.53) | ALDH1A1SMN1; SMN2PKMRAB9ATP53 | |
| SCHEMBL6188761 | 0.86 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL4035588 | 0.84 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL1382447 | 0.83 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL4038120 | 0.83 | GAA (0.49) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4032832 | 0.82 | MEN1 (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL4038593 | 0.81 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2PKMRAB9APOLB | |
| SCHEMBL4032579 | 0.81 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4033588 | 0.80 | USP2 (0.54) | ALDH1A1SMN1; SMN2PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | claimed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | MEN1 4821/4885KMT2A 396/4885ALDH1A1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.